Optimization of (arylpiperazinylbutyl)oxindoles exhibiting selective 5-HT 7 receptor antagonist activity

Journal of Medicinal Chemistry

Volumn 54, Issue 19, 2011, Pages 6657-6669

  Volk, Balázs ^a   Gacsályi, István ^a   Pallagi, Katalin ^a   Poszávácz, László ^a   Gyönös, Ildikó ^a   Szabó, Éva ^a   Bakó, Tibor ^a   Spedding, Michael ^b   Simig, Gyula ^a   Szénási, Gábor ^a  

^a EGIS PHARMACEUTICALS LTD   (Hungary)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

(ARYLPIPERAZINYLBUTYL)OXINDOLE; 3 [4 (4 PHENYLPIPERAZIN 1 YL)BUTYL] 1,3 DIHYDRO 2H INDOL 2 ONE; 3 [4 [ (3 CHLOROPHENYL)PIPERAZIN 1 YL]BUTYL] 6 FLUORO 1,3 DIHYDRO 2H INDOL 2 ONE OXALATE; 3 [4 [4 (4 CHLOROPHENYL)PIPERAZIN 1 YL]BUTYL] 5 FLUORO 1,3 DIHYDRO 2H INDOL 2 ONE HYDROCHLORIDE; 4 (3,5,7 TRICHLORO 2 OXO 2,3 DIHYDRO 1H INDOL 3 YL)BUTYL METHANESULFONATE; 4 (5,7 DICHLORO 2 OXO 2,3 DIHYDRO 1H INDOL 3 YL)BUTYL METHANESULFONATE; 4 (6 FLUORO 2 OXO 2,3 DIHYDRO 1H INDOL 3 YL)BUTYL METHANESULFONATE; 5,7 DICHLORO 3 (4 CHLOROBUTYL) 3 ETHYL 6 FLUOROOXINDOLE; 5,7 DICHLORO 3 [4 [4 (3 CHLOROPHENYL)PIPERAZIN 1 YL]BUTYL] 3 ETHYL 6 FLUORO 1,3 DIHYDRO 2H INDOL 2 ONE HYDROCHLORIDE; 5,7 DICHLORO 3 [4 [4 (4 CHLOROPHENYL)PIPERAZIN 1 YL]BUTYL] 1,3 DIHYDRO 2H INDOL 2 ONE; 5,7 DICHLORO 3 [4 [4 (4 CHLOROPHENYL)PIPERAZIN 1 YL]BUTYL] 3 ETHYL 6 FLUORO 1,3 DIHYDRO 2H INDOL 2 ONE HYDROCHLORIDE; OXINDOLE; SEROTONIN 1A RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG;

ADRENERGIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; FORCED SWIMMING TEST; LIGHT DARK CYCLE; MOUSE; NONHUMAN; RAT; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; BINDING SITES; BRAIN; CHO CELLS; CRICETINAE; CRICETULUS; INDOLES; LIGANDS; MALE; MICE; MICROSOMES, LIVER; PIPERAZINES; RADIOLIGAND ASSAY; RATS; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 80053927380     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200547z     Document Type: Article

References (76)

1. Hoyer, D.; Hannon, J. P.; Martin, G. R. Molecular, pharmacological and functional diversity of 5-HT receptors Pharmacol., Biochem. Behav. 2002, 71, 533-554 (Pubitemid 34219205)
2. 7 J. Med. Chem. 2003, 46, 2795-2810
3. 7 receptor gene expression in the rat hippocampus Mol. Brain Res. 1997, 45, 182-186 (Pubitemid 27182244)
4. 7 receptor-mediated cyclic adenosine monophosphate accumulation in rat frontocortical astrocytes J. Pharmacol. Exp. Ther. 1996, 279, 1551-1558
5. 7 receptor binding sites in rat hypothalamus: Sensitivity to chronic antidepressant treatment Mol. Pharmacol. 1995, 47, 99-103
6. Schwartz, W. J. A clinician's primer on the circadian clock: its localization, function, and resetting Adv. Intern. Med. 1993, 38, 81-106
7. 7 receptor antagonist SB 269970 in animal models of anxiety and depression Neuropharmacology 2006, 51, 578-586 (Pubitemid 44215962)
8. 7 receptor suggest therapeutic potential in depression Neuropharmacology 2005, 48, 492-502 (Pubitemid 40332407)
9. 7 receptor antagonists Curr. Med. Chem. 2004, 4, 203-214 (Pubitemid 39061898)
10. 7 receptor regulation in the rat hypothalamus Neuropsychopharmacology 1999, 21, 352-367 (Pubitemid 29333073)
11. 7 receptor antagonist, in mouse models predictive of antipsychotic-like activity Behav. Pharmacol. 2008, 19, 153-159 (Pubitemid 351365693)
12. 7 receptors in the facilitatory response induced by 8-OH-DPAT on learning consolidation Behav. Brain Res. 2001, 21, 21-28 (Pubitemid 32223462)
13. Roth, B. L.; Craigo, S. C.; Choudharmy, M. S.; Uluer, A.; Monsma, J. F.; Shen, Y.; Meltzer, Y. H., Jr.; Sibley, R. D. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors J. Pharmacol. Exp. Ther. 1994, 268, 1403-1410 (Pubitemid 24100360)
14. 7Rs) and their ligands Curr. Med. Chem. 2004, 11, 629-661 (Pubitemid 38380040)
15. 7 Receptor ligands: Recent developments and potential therapeutic applications Mini-Rev. Med. Chem. 2007, 7, 945-960 (Pubitemid 47554783)
16. Bojarski, A. J. Pharmacophore models for metabotropic 5-HT receptor ligands Curr. Top. Med. Chem. 2006, 6, 2005-2026 (Pubitemid 44524474)
17. 7 receptor modulators: a medicinal chemistry survey of recent patent literature (2004-2009) Exp. Opin. Ther. Pat. 2010, 20, 739-754
18. 7 receptor antagonists as a new class of antidepressants Drug News Perspect. 2007, 20, 613-618 (Pubitemid 351437589)
19. 7 receptor antagonists J. Med. Chem. 2008, 51, 2522-2532 (Pubitemid 351628514)
20. 7 receptors J. Comput.-Aided Mol. Des. 2001, 15, 883-909 (Pubitemid 34218292)
21. Vogel, J. R.; Beer, B.; Clody, D. E. A simple and reliable conflict procedure for testing antianxiety agents Psychopharmacologia (Berlin, Ger.). 1971, 21, 1-7
22. Costall, B.; Jones, B. J.; Kelly, M. E.; Naylor, R. J.; Tomkins, D. M. Exploration of mice in a black and white test box: validation as a model of anxiety Pharm. Biochem. Behav. 1989, 32, 777-785 (Pubitemid 19162403)
23. 1-adrenoceptor antagonists Bioorg. Med. Chem. Lett. 2008, 18, 5140-5145
24. 1- adrenoceptor antagonist activity, and SAR study of novel arylpiperazine derivatives of phenytoin Bioorg. Med. Chem. 2008, 16, 5982-5998 (Pubitemid 351758841)
25. 1-adrenergic receptor using the E-state index Bioorg. Med. Chem. Lett. 2003, 13, 2837-2842 (Pubitemid 37386235)
26. Kaster, M. P.; Raupp, I.; Binfaré, R. W.; Andreatini, R.; Rodrigues, A. L. Antidepressant-like effect of lamotrigine in the mouse forced swimming test: evidence for the involvement of the noradrenergic system Eur. J. Pharmacol. 2007, 565, 119-124 (Pubitemid 46795482)
27. 1-adrenoceptors in the antidepressant-like effect of chlorpheniramine in the mouse tail suspension test Eur. J. Pharmacol. 2007, 562, 72-76 (Pubitemid 46466761)
28. Popp, F. D. The chemistry of isatin. In Advances in Heterocyclic Chemistry; Katritzky, A. R.; Boulton, A. J., Eds.; Academic Press: New York, 1975; Vol. 18, pp 2-5; and references cited therein.
29. Volk, B.; Simig, G. New one-pot synthesis of 3-alkyl- and 3-(ω-hydroxyalkyl)oxindoles from isatins Eur. J. Org. Chem. 2003, 3991-3996
30. Kende, A. S.; Hodges, J. C. Regioselective C-3 alkylations of oxindole dianion Synth. Commun. 1982, 12, 1-10
31. Fuchs, J. R.; Funk, R. L. Indol-2-one intermediates: mechanistic evidence and synthetic utility. Total syntheses of (±)-flustramines A and C Org. Lett. 2005, 7, 677-680 (Pubitemid 40353469)
32. Rossiter, Sh. A convenient synthesis of 3-methyleneoxindoles: cytotoxic metabolites of indole-3-acetic acids Tetrahedron Lett. 2002, 43, 4671-4673
33. Volk, B.; Barkóczy, J.; Simig, G.; Mezei, T.; Kapiller- Dezsöfi, R.; Gacsályi, I.; Pallagi, K.; Gigler, G.; Lévay, G.; Móricz, K.; Leveleki, C.; Sziray, N.; Szénási, G.; Egyed, A.; Hársing, L. G. Preparation of indol-2-one derivatives for the treatment of central nervous disorders, gastrointestinal disorders and cardiovascular disorders. WO 2005108390, 2005; Chem. Abstr. 2005, 143, 477847.
34. Volk, B.; Barkóczy, J.; Simig, G.; Mezei, T.; Kapiller- Dezsöfi, R.; Gacsályi, I.; Pallagi, K.; Gigler, G.; Lévay, G.; Móricz, K.; Leveleki, C.; Sziray, N.; Szénási, G.; Egyed, A.; Hársing, L. G. Preparation of pyridine derivatives of alkyl oxindoles as 5-HT7 receptor active agents. WO 2005108388, 2005; Chem. Abstr. 2005, 143, 477850.
35. 7 receptor active agents for treating or preventing central nervous system or cardiovascular system disorders. WO 2005108363, 2005; Chem. Abstr. 2005, 143, 477984.
36. Volk, B.; Barkóczy, J.; Simig, G.; Mezei, T.; Kapiller- Dezsöfi, R.; Gacsályi, I.; Pallagi, K.; Gigler, G.; Lévay, G.; Móricz, K.; Leveleki, C.; Sziray, N.; Szénási, G.; Egyed, A.; Hársing, L. G. Preparation of piperazine derivatives of alkyl oxindoles for treating or preventing central nervous system or cardiovascular disorders. WO 2005108364, 2005; Chem. Abstr. 2005, 143, 477985.
37. 1 receptors for use against central nervous system and other diseases. WO 2005109987, 2005; Chem. Abstr. 2005, 143, 477989.
38. Lucki, I.; Dalvi, A; Mayorga, A. J. Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice Psychopharmacology (Berlin, Ger.) 2001, 155, 315-322 (Pubitemid 32477289)
39. Petit-Demouliere, B.; Chenu, F.; Bourin, M. Forced swimming test in mice: a review of antidepressant activity Psychopharmacology (Berlin, Ger.) 2005, 177, 245-255 (Pubitemid 40137284)
40. Pollak, D. D.; Rey, C. E.; Monje, F. J. Rodent models in depression research: classical strategies and new directions Ann. Med. 2010, 42, 252-264
41. 7 receptor antagonists Bioorg. Med. Chem. 2008, 16, 5405-5412 (Pubitemid 351694490)
42. 7 receptor ligands Bioorg. Med. Chem. 2008, 16, 2570-2578 (Pubitemid 351380927)
43. Due to its special properties (high electronegativity and small size), fluorine substituent is widely used in medicinal chemistry for the exploration of structure-activity relationships, see: Shah, P.; Westwell, A. D. The role of fluorine in medicinal chemistry J. Enzyme Inhib. Med. Chem. 2007, 22, 527-540
44. 7 receptor ligands Bioorg. Med. Chem. Lett. 2002, 12, 2451-2454 (Pubitemid 34879888)
45. 1A receptors J. Pharm. Pharmacol. 2004, 56, 247-255 (Pubitemid 38232755)
46. Wisłowska-Stanek, A.; Zienowicz, M.; Lehner, M.; Taracha, E.; Bidziński, A.; Maciejak, P.; Skórzewska, A.; Szyndler, J.; Płaźnik, A. Buspirone attenuates conditioned fear-induced c-Fos expression in the rat hippocampus Neurosci. Lett. 2005, 389, 115-120 (Pubitemid 41242896)
47. Vaidya, A. H.; Rosenthal, D. I.; Lang, W.; Crooke, J. J.; Benjamin, D.; Ilyin, S. E.; Reitz, A. B. Oral buspirone causes a shift in the dose-response curve between the elevated-plus maze and Vogel conflict tests in Long-Evans rats: relation of brain levels of buspirone and 1-PP to anxiolytic action Methods Find. Exp. Clin. Pharmacol. 2005, 27, 245-255 (Pubitemid 40677038)
48. 1A receptor in modulating anxiety-related behaviors J. Neurosci. 2010, 30, 2433-2441
49. 1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats Br. J. Pharmacol. 2009, 156, 181-188
50. 1A receptor agents Eur. J. Pharmacol. 2005, 508, 155-158 (Pubitemid 40169914)
51. Briones-Aranda, A.; López-Rubalcava, C.; Picazo, O. Influence of forced swimming-induced stress on the anxiolytic-like effect of 5HT(1A) agents in mice Psychopharmacology (Berlin, Ger.) 2002, 162, 147-155 (Pubitemid 34743954)
52. 1A receptors and the anxiolytic-like effect of 8-OH-DPAT in rats Pharmacol., Biochem. Behav. 2009, 92, 182-189
53. Wustrow, D.; Belliotti, T.; Glase, S.; Kesten, S. R.; Johnson, D.; Colbry, N.; Rubin, R.; Blackburn, A.; Akunne, H.; Corbin, A.; Davis, M. D.; Georgic, L.; Whetzel, S.; Zoski, K.; Heffner, T.; Pugsley, T.; Wise, L. Aminopyrimidines with high affinity for both serotonin and dopamine receptors J. Med. Chem. 1998, 41, 760-771 (Pubitemid 28114885)
54. 1 receptors. Part 6 Bioorg. Med. Chem. 2000, 8, 873-881 (Pubitemid 30336383)
55. 1A receptor ligands as conformationally constrained analogues of 4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]-1-arylpiperazines J. Med. Chem. 2001, 44, 4431-4442 (Pubitemid 33131667)
56. 7 serotonin receptor ligands Bioorg. Med. Chem. 2007, 15, 5239-5250 (Pubitemid 46880370)
57. 1A agonist 8-hydroxy-2-(di- n -propylamino) tetralin (8-OH-DPAT) Eur. J. Pharmacol. 1988, 154, 339-341
58. 1A receptor ligands Bioorg. Med. Chem. Lett. 2005, 15, 1185-1188 (Pubitemid 40458670)
59. 1A receptor ligands Bioorg. Med. Chem. 2006, 16, 3406-3410 (Pubitemid 43792526)
60. 1A receptor antagonists J. Med. Chem. 1999, 42, 4952-4960
61. 1A receptor in vivo J. Pharm. Exp. Ther. 1995, 273, 1418-1427
62. 1A functional characteristics Bioorg. Med. Chem. 2005, 13, 2293-2303 (Pubitemid 40261146)
63. 7 receptor affinity and in vivo pharmacological properties of some new 1-(m -trifluoromethylphenyl)piperazines Bioorg. Med. Chem. 2007, 15, 7116-7125 (Pubitemid 47451781)
64. 1A serotonin receptor ligands J. Med. Chem. 2008, 51, 4529-4538
65. Lepor, J. P. The emerging role of alpha antagonists in the therapy of benign prostatic hyperplasia Andrologia 1991, 12, 389-394
66. Caine, M. Alpha-adrenergic blockers for treatment of benign prostatic hyperplasia Urol. Clin. North. Am. 1990, 17, 641-649 (Pubitemid 20220207)
67. Russell, R. K.; Press, J. B.; Rampulla, R. A.; McNally, J. J.; Keiser, J. A.; Bright, D. A.; Tobia, A. Thiophene systems. 9. Thienopyrimidinedione derivatives as potential antihypertensive agents J. Med. Chem. 1988, 31, 1786-1793
68. Kasztreiner, E.; Mátyus, P.; Rablóczky, G.; Jaszlits, L. GYKI-12743 Drugs Fut. 1989, 14, 622-624 (Pubitemid 19201496)
69. 1A receptor of 1-aryl-4-[(1-tetralin)alkyl] piperazines. 2 J. Med. Chem. 1995, 38, 942-949
70. Koyama, M.; Kikuchi, C.; Ushiroda, O.; Ando, T.; Nagaso, H.; Fuji, K.; Okuno, M.; Hiranuma, T. Preparation of tetrahydrobenzindole derivatives for the treatment or prevention of mental diseases. WO 9800400 (EP 937715), 1997; Chem. Abstr. 1997, 128, 114961.
71. 7 receptor J. Med. Chem. 1999, 42, 533-535 (Pubitemid 29110768)
72. 7 receptor J. Med. Chem. 2002, 45, 2197-2206 (Pubitemid 34525799)
73. 7 receptor Bioorg. Med. Chem. Lett. 2002, 12, 2549-2552 (Pubitemid 35245278)
74. 7 antagonists with increased in vitro metabolic stability Bioorg. Med. Chem. Lett. 2003, 13, 61-64 (Pubitemid 35447685)
75. 7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders. Pharmacol. Ther. 2011, 129, 120-148; and references cited therein.
76. 3H]spiroperidol Mol. Pharmacol. 1979, 16, 687-699 (Pubitemid 10203525)